BattellePharma and Pharmacia Corporation to Develop Inhaled Pharmaceutical Treatment.Business Editors and Health/Medical Writers COLUMBUS, Ohio--(BW HealthWire)--Aug. 20, 2002 BattellePharma announced today that it signed an agreement with Pharmacia Corporation (NYSE NYSE See: New York Stock Exchange :PHA PHA abbr. phytohemagglutinin PHA phytohemagglutinin, a plant lectin. ) to develop an existing Pharmacia compound using BattellePharma's Mystic(TM) inhalation technology as the delivery vehicle. The deal includes an upfront payment and a mutually agreed upon Adj. 1. agreed upon - constituted or contracted by stipulation or agreement; "stipulatory obligations" stipulatory noncontroversial, uncontroversial - not likely to arouse controversy development plan through clinical proof-of-concept. This is the ninth product in BattellePharma's pipeline, which includes inhalable treatments for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , asthma, chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. and other systemic diseases. BattellePharma's products are based on its three platform technologies: Mystic(TM) inhalation technology, novel formulation technologies, and inhaled anticancer therapy. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases and lung cancer. Pharmacia is the seventh pharmaceutical company to form a partnership with BattellePharma with the intent to develop products based on BattellePharma's expertise in developing novel formulations for inhaled delivery by Mystic. "Pharmacia is very strong in developing and marketing products in a number of therapeutic categories throughout the world, so we are pleased to develop a relationship with them," said Dennis Cearlock, BattellePharma's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "In addition to our internal efforts to develop new compounds and therapies, strategic partnerships with leading pharmaceutical companies, such as Pharmacia, help us realize the full potential of our Mystic technology." About BattellePharma BattellePharma is a pre-public specialty pharmaceutical company leveraging science and technology to design more effective medicines. BattellePharma has partnerships with numerous pharmaceutical corporations including Abbott Laboratories, Corus Pharma, GlaxoSmithKline, Pfizer Inc., Pharmacia Corporation, Viasys Healthcare, and ViroPharma Inc., and is a subsidiary of Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , the world's largest independent and private research and development organization. For more information on BattellePharma, reference the company's website at www.battellepharma.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion